Kyung-Hwak Yoon, Yeshong Park, Eunyoung Kang, Eun-Kyu Kim, Jee Hyun Kim, Se Hyun Kim, Koung Jin Suh, Sun Mi Kim, Mijung Jang, Bo La Yun, So Yeon Park, Hee-Chul Shin
Cancer Res Treat. 2022;54(4):1081-1090. Published online November 17, 2021
Purpose Estrogen receptor (ER) expression in breast cancer plays an essential role in carcinogenesis and disease progression. Recently, tumors with low level (1%-10%) of ER expression have been separately defined as ER low positive (ERlow). It is suggested that ERlow tumors might be morphologically and behaviorally different from tumors with high ER expression (ERhigh).
Materials and Methods Retrospective analysis of a prospective cohort database was performed. Patients who underwent curative surgery for early breast cancer and had available medical records were included for analysis. Difference in clinicopathological characteristics, endocrine responsiveness and five-year recurrence-free survival was evaluated between different ER subgroups (ERhigh, ERlow, and ER-negative [ER–]).
Results A total of 2,162 breast cancer patients were included in the analysis, Tis and T1 stage. Among them, 1,654 (76.5%) were ERhigh, 54 (2.5%) were ERlow, and 454 (21.0%) were ER- patients. ERlow cases were associated with smaller size, higher histologic grade, positive human epidermal growth factor receptor 2, negative progesterone receptor, and higher Ki-67 expression. Recurrence rate was highest in ER– tumors and was inversely proportional to ER expression. Recurrence-free survival was not affected by hormonal therapy in the ERlow group (p=0.418).
Conclusion ERlow breast cancer showed distinct clinicopathological features. ERlow tumors seemed to have higher recurrence rates compared to ERhigh tumors, and they showed no significant benefit from hormonal therapy. Future large scale prospective studies are necessary to validate the treatment options for ERlow breast cancer.
Citations
Citations to this article as recorded by
ER-positive and BRCA2-mutated breast cancer: a literature review Pu-Chun Li, Yi-Fan Zhu, Wen-Ming Cao, Bei Li European Journal of Medical Research.2024;[Epub] CrossRef
Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy Nina Eissler, Renske Altena, Ali Alhuseinalkhudhur, Olga Bragina, Joachim Feldwisch, Guido Wuerth, Annika Loftenius, Nikolai Brun, Rimma Axelsson, Vladimir Tolmachev, Jens Sörensen, Fredrik Y. Frejd Biomedicines.2024; 12(5): 1088. CrossRef
Distinct ER and PR expression patterns significantly affect the clinical outcomes of early HER2-positive breast cancer: A real-world analysis of 871 patients treated with neoadjuvant therapy Haizhu Chen, Xiujuan Gui, Ziwei Zhou, Fengxi Su, Chang Gong, Shunrong Li, Wei Wu, Nanyan Rao, Qiang Liu, Herui Yao The Breast.2024; 75: 103733. CrossRef
HR-positive/HER2-negative breast cancer arising in patients with or without BRCA2 mutation: different biological phenotype and similar prognosis Pu-Chun Li, Yi-Fan Zhu, Jia-Ni Pan, Qiao-Yan Zhu, Yu-Yang Liao, Xiao-Wen Ding, Lin-Feng Zheng, Wen-Ming Cao Therapeutic Advances in Medical Oncology.2024;[Epub] CrossRef
Is the percentage of hormone receptor positivity in HR+ HER2-metastatic breast cancer patients receiving CDK 4/6 inhibitor with endocrine therapy predictive and prognostic? Merve Keskinkilic, Huseyin Salih Semiz, Tugba Yavuzsen, Ilhan Oztop Frontiers in Oncology.2024;[Epub] CrossRef
Rat Models of Hormone Receptor-Positive Breast Cancer Raquel Nicotra, Catrin Lutz, Hendrik A. Messal, Jos Jonkers Journal of Mammary Gland Biology and Neoplasia.2024;[Epub] CrossRef
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer Davide Massa, Claudio Vernieri, Lorenzo Nicolè, Carmen Criscitiello, Florence Boissière-Michot, Séverine Guiu, Angélique Bobrie, Gaia Griguolo, Federica Miglietta, Andrea Vingiani, Riccardo Lobefaro, Beatrice Taurelli Salimbeni, Claudia Pinato, Francesca JNCI: Journal of the National Cancer Institute.2024; 116(12): 1914. CrossRef
Trends in the incidence and survival of women with hormone receptor-positive breast cancer from 1990 to 2019: a large population-based analysis Hongbo Huang, Tingting Wei, Aijie Zhang, Heng Zhang, Lingquan Kong, Yunhai Li, Fan Li Scientific Reports.2024;[Epub] CrossRef
The “lows”: Update on ER-low and HER2-low breast cancer Nicola Fusco, Giuseppe Viale The Breast.2024; 78: 103831. CrossRef
Estrogenized HSA induced high-affinity autoantibodies in breast cancer - Novel biomarker for early detection Subuhi Sherwani, Mohd Wajid Ali Khan, Wahid Ali Khan, Saravanan Rajendrasozhan, Khalid Al-Motair, Hamda Khan, Saheem Ahmad Frontiers in Oncology.2024;[Epub] CrossRef
Transcription factors and hormone receptors: Sex‑specific targets for cancer therapy (Review) Juyeon Kim, Hyobin Bang, Cheyun Seong, Eun-Sook Kim, Sun Kim Oncology Letters.2024;[Epub] CrossRef
Impact of prolactin treatment on enhancing the cellular responses of MCF7 breast cancer cells to tamoxifen treatment Anwar Shams Discover Oncology.2024;[Epub] CrossRef
Missing link between tissue specific expressing pattern of ERβ and the clinical manifestations in LGBLEL Xujuan Zhang, Pengxiang Zhao, Mingshen Ma, Hao Wu, Rui Liu, Ziyi Liu, Zisong Cai, Mengyu Liu, Fei Xie, Xuemei Ma Frontiers in Medicine.2023;[Epub] CrossRef
Assessment of breast cytoarchitecture and its associated axillary lymph node status under normal and pathological conditions in Egyptian women Omnia Mansour, Amani Kazem, Abeer El Wakil Tissue and Cell.2023; 85: 102244. CrossRef
Estrogen-Receptor-Low-Positive Breast Cancer: Pathological and Clinical Perspectives Christina Panagiotis Malainou, Nikolina Stachika, Aikaterini Konstantina Damianou, Aristotelis Anastopoulos, Ioanna Ploumaki, Efthymios Triantafyllou, Konstantinos Drougkas, Georgia Gomatou, Elias Kotteas Current Oncology.2023; 30(11): 9734. CrossRef
Purpose
Alteration of biomarker status after primary systemic therapy (PST) is occasionally found in breast cancer. This study was conducted to clarify the clinical implications of change of biomarker status in breast cancer patients treated with PST.
Materials and Methods
The pre-chemotherapeutic biopsy and post-chemotherapeutic resection specimens of 442 breast cancer patients who had residual disease after PST were included in this study. The association between changes of biomarker status after PST and clinicopathologic features of tumors, and survival of the patients, were analyzed.
Results
Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status changed after PST in 18 (4.1%), 80 (18.1%), and 15 (3.4%) patients,respectively. ER and PR mainly underwent positive to negative conversion,whereas HER2 status underwent negative to positive conversion. Negative conversion of ER and PR status after PST was associated with reduced disease-free survival. Moreover, a decline in the Allred score for PR in post-PST specimens was significantly associated with poor clinical outcome of the patients. HER2 change did not have prognostic significance. In multivariate analyses, negative PR status after PST was found to be an independent adverse prognostic factor in the whole patient group, in the adjuvant endocrine therapy-treated subgroup, and also in pre-PST PR positive subgroup.
Conclusion
ER and HER2 status changed little after PST, whereas PR status changed significantly. In particular, negative conversion of PR status was revealed as a poor prognostic indicator, suggesting that re-evaluation of basic biomarkers is mandatory in breast cancer after PST for proper management and prognostication of patients.
Citations
Citations to this article as recorded by
Changing the phenotype of breast cancer in the process treatment: literature review M. S. Shvedsky, R. I. Tamrazov, T. P. Shevlyukova, L. A. Bakhova Surgery and Oncology.2024; 13(4): 50. CrossRef
HER2-low breast cancer and response to neoadjuvant chemotherapy: a population-based cohort study Ximena Baez-Navarro, Mieke R. van Bockstal, Agnes Jager, Carolien H.M. van Deurzen Pathology.2024; 56(3): 334. CrossRef
NGS mutational status on first diagnostic tissue, liquid biopsy and mastectomy in G2–G3 breast cancer Carmen Maria Ardeleanu, Maria Victoria Olinca , Cristian Gabriel Viişoreanu , Horaţiu Alin Mureşan , Adriana Tecuceanu-Vulpe , Georgiana Manole , Iulia Elena Gune , Bianca Gălăţeanu , Andreea-Corina Ilie-Petrov Romanian Journal of Morphology and Embryology.2024; 65(2): 195. CrossRef
Applicability of Quantum Dots in Breast Cancer Diagnostic and Therapeutic Modalities—A State-of-the-Art Review Dominika Kunachowicz, Karolina Kłosowska, Natalia Sobczak, Marta Kepinska Nanomaterials.2024; 14(17): 1424. CrossRef
Establishment and evaluation of digital PCR methods for HER2 copy number variation in breast cancer Xia Wang, Dechun Xing, Zheng Liu, Yujing Zhang, Bo Cheng, Suozhu Sun, Qingtao Wang, Lianhua Dong Analytical and Bioanalytical Chemistry.2023; 415(4): 725. CrossRef
Clinical significance and prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients Yang He, Jing Zhang, Hui Chen, Ying Zhou, Liping Hong, Yue Ma, Nannan Chen, Weipeng Zhao, Zhongsheng Tong Frontiers in Surgery.2023;[Epub] CrossRef
Conversion of ER and HER2 Status After Neoadjuvant Therapy in Chinese Breast Cancer Patients Jiaqi Bo, Baohua Yu, Rui Bi, Xiaoli Xu, Yufan Cheng, Xiaoyu Tu, Qianming Bai, Wentao Yang, Ruohong Shui Clinical Breast Cancer.2023; 23(4): 436. CrossRef
Récepteur du facteur de croissance épidermique HER2, tests utilisés pour rechercher son amplification dans le cancer du sein : principes et limites Imane Eliahiai, Mohammed Eljiar, Sanae Chaib, Jinane KHarmoum, Mariame Chraïbi Bulletin du Cancer.2023; 110(12): 1301. CrossRef
HER2 changes to positive after neoadjuvant chemotherapy in breast cancer: A case report and literature review Luo Wang, Qi Jiang, Meng-Ye He, Peng Shen World Journal of Clinical Cases.2022; 10(1): 260. CrossRef
Experience with olaparib in a patient with luminal HER2-positive metastatic breast cancer L. V. Bolotina, A. L. Kornietskaya, A. A. Kachmazov, N. S. Prizova, A. A. Paichadze, T. V. Ustinova, T. I. Deshkina, S. F. Evdokimova Meditsinskiy sovet = Medical Council.2022; (9): 179. CrossRef
Machine learning on MRI radiomic features: identification of molecular subtype alteration in breast cancer after neoadjuvant therapy Hai-Qing Liu, Si-Ying Lin, Yi-Dong Song, Si-Yao Mai, Yue-dong Yang, Kai Chen, Zhuo Wu, Hui-Ying Zhao European Radiology.2022; 33(4): 2965. CrossRef
Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer Mengping Long, Chong You, Qianqian Song, Lina Hu, Zhaorong Guo, Qian Yao, Wei Hou, Wei Sun, Baosheng Liang, Xiao-Hua Zhou, Yiqiang Liu, Taobo Hu Life.2022; 13(1): 74. CrossRef
The impact of progesterone receptor negativity on oncological outcomes in oestrogen-receptor-positive breast cancer M G Davey, É J Ryan, P J Folan, N O’Halloran, M R Boland, M K Barry, K J Sweeney, C M Malone, R J McLaughlin, M J Kerin, A J Lowery BJS Open.2021;[Epub] CrossRef
Prognostic implications of regression of metastatic axillary lymph nodes after neoadjuvant chemotherapy in patients with breast cancer Yul Ri Chung, Ji Won Woo, Soomin Ahn, Eunyoung Kang, Eun-Kyu Kim, Mijung Jang, Sun Mi Kim, Se Hyun Kim, Jee Hyun Kim, So Yeon Park Scientific Reports.2021;[Epub] CrossRef
Enriched transcriptome analysis of laser capture microdissected populations of single cells to investigate intracellular heterogeneity in immunostained FFPE sections Sarah M. Hammoudeh, Arabella M. Hammoudeh, Thenmozhi Venkatachalam, Surendra Rawat, Manju N. Jayakumar, Mohamed Rahmani, Rifat Hamoudi Computational and Structural Biotechnology Journal.2021; 19: 5198. CrossRef
Lost but Not Least—Novel Insights into Progesterone Receptor Loss in Estrogen Receptor-Positive Breast Cancer Michał Kunc, Marta Popęda, Wojciech Biernat, Elżbieta Senkus Cancers.2021; 13(19): 4755. CrossRef
Biomarkers Changes after Neoadjuvant Chemotherapy in Breast Cancer: A Seven-Year Single Institution Experience Saverio Coiro, Elisa Gasparini, Giuseppe Falco, Giacomo Santandrea, Moira Foroni, Giulia Besutti, Valentina Iotti, Roberto Di Cicilia, Monica Foroni, Simone Mele, Guglielmo Ferrari, Giancarlo Bisagni, Moira Ragazzi Diagnostics.2021; 11(12): 2249. CrossRef
HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation Soomin Ahn, Ji Won Woo, Kyoungyul Lee, So Yeon Park Journal of Pathology and Translational Medicine.2020; 54(1): 34. CrossRef
Effect of neoadjuvant therapy on breast cancer biomarker profile Laura Rey-Vargas, Juan Carlos Mejía-Henao, María Carolina Sanabria-Salas, Silvia J. Serrano-Gomez BMC Cancer.2020;[Epub] CrossRef
Changes in Biomarker Status in Metastatic Breast Cancer and Their Prognostic Value Ji Won Woo, Yul Ri Chung, Soomin Ahn, Eunyoung Kang, Eun-Kyu Kim, Se Hyun Kim, Jee Hyun Kim, In Ah Kim, So Yeon Park Journal of Breast Cancer.2019; 22(3): 439. CrossRef
Yu Jin Lim, Sea-Won Lee, Noorie Choi, Jeanny Kwon, Keun-Yong Eom, Eunyoung Kang, Eun-Kyu Kim, Jee Hyun Kim, Yu Jung Kim, Se Hyun Kim, So Yeon Park, In Ah Kim
Cancer Res Treat. 2018;50(4):1140-1148. Published online December 7, 2017
Purpose
This study aimed to identify predictors for distant metastatic behavior and build a related prognostic nomogram in breast cancer.
Materials and Methods
A total of 1,181 patients with non-metastatic breast cancer between 2003 and 2011 were analyzed. To predict the probability of distant metastasis, a nomogram was constructed based on prognostic factors identified using a Cox proportional hazards model.
Results
The 7-year overall survival and 5-year post-progression survival of locoregional versus distant recurrence groups were 67.6% versus 39.1% (p=0.027) and 54.2% versus 33.5% (p=0.043), respectively. Patients who developed distant metastasis showed early and late mortality risk peaks within 3 and after 5 years of follow-up, respectively, but a broad and low risk increment was observed in other patients with locoregional relapse. In multivariate analysis of distant metastasis-free interval, age (≥ 45 years vs. < 45 years), molecular subtypes (luminal A vs. luminal B, human epidermal growth receptor 2, and triple negative), T category (T1 vs. T2-3 and T4), and N category (N0 vs. N1 and N2-3) were independently associated (p < 0.05 for all). Regarding the significant factors, a well-validated nomogram was established (concordance index, 0.812). The risk score level of patients with initial brain failure was higher than those of non-brain sites (p=0.029).
Conclusion
The nomogram could be useful for predicting the individual probability of distant recurrence in breast cancer. In high-risk patients based on the risk scores, more aggressive systemic therapy and closer surveillance for metastatic failure should be considered.
Citations
Citations to this article as recorded by
Predicting Patterns of Distant Metastasis in Breast Cancer Patients following Local Regional Therapy Using Machine Learning Audrey Shiner, Alex Kiss, Khadijeh Saednia, Katarzyna J. Jerzak, Sonal Gandhi, Fang-I Lu, Urban Emmenegger, Lauren Fleshner, Andrew Lagree, Marie Angeli Alera, Mateusz Bielecki, Ethan Law, Brianna Law, Dylan Kam, Jonathan Klein, Christopher J. Pinard, Ale Genes.2023; 14(9): 1768. CrossRef
Nomograms for Predicting Specific Distant Metastatic Sites and Overall Survival of Breast Invasive Ductal Carcinoma Patients After Surgery: A Large Population-Based Study Yuqian Feng, Yiting Zhang, Yuying Xiang, Kaibo Guo, Huimin Jin, Shanming Ruan, Zhuoya Guan Frontiers in Surgery.2022;[Epub] CrossRef
Cost-effectiveness of postmastectomy hypofractionated radiation therapy vs conventional fractionated radiation therapy for high-risk breast cancer Jing Yang, Shu-Nan Qi, Hui Fang, Yong-Wen Song, Jing Jin, Yue-Ping Liu, Wei-Hu Wang, Yong Yang, Yu Tang, Hua Ren, Bo Chen, Ning-Ning Lu, Yuan Tang, Ning Li, Hao Jing, Shu-Lian Wang, Ye-Xiong Li The Breast.2021; 58: 72. CrossRef
Prediction of distant metastatic recurrence by tumor-infiltrating lymphocytes in hormone receptor-positive breast cancer Koji Takada, Shinichiro Kashiwagi, Yuka Asano, Wataru Goto, Rika Kouhashi, Akimichi Yabumoto, Sae Ishihara, Tamami Morisaki, Masatsune Shibutani, Hiroaki Tanaka, Kosei Hirakawa, Masaichi Ohira BMC Women's Health.2021;[Epub] CrossRef
Nomogram for the personalisation of radiotherapy treatments in breast cancer patients Inmaculada Beato Tortajada, Carlos Ferrer Albiach, Virginia Morillo Macias The Breast.2021; 60: 255. CrossRef
Prognostic Factors and Nomograms to Predict Overall and Cancer-Specific Survival for Children with Wilms’ Tumor Fucai Tang, Hanbin Zhang, Zechao Lu, Jiamin Wang, Chengwu He, Zhaohui He Disease Markers.2019; 2019: 1. CrossRef
Score for the Survival Probability in Metastasis Breast Cancer: A Nomogram-Based Risk Assessment Model Zhenchong Xiong, Guangzheng Deng, Xinjian Huang, Xing Li, Xinhua Xie, Jin Wang, Zeyu Shuang, Xi Wang Cancer Research and Treatment.2018; 50(4): 1260. CrossRef
Koung Jin Suh, Se Hyun Kim, Kyung-Hun Lee, Tae-Yong Kim, Yu Jung Kim, Sae-Won Han, Eunyoung Kang, Eun-Kyu Kim, Kidong Kim, Jae Hong No, Wonshik Han, Dong-Young Noh, Maria Lee, Hee Seung Kim, Seock-Ah Im, Jee Hyun Kim
Cancer Res Treat. 2017;49(4):1153-1163. Published online February 27, 2017
Purpose
Although combining aromatase inhibitors (AI) with gonadotropin-releasing hormone agonists (GnRHa) is becoming more common, it is still not clear if GnRHa is as effective as bilateral salpingo-oophorectomy (BSO).
Materials and Methods
We retrospectively analyzed data of 66 premenopausal patients with hormone receptor– positive, human epidermal growth factor receptor 2–negative recurrent and metastatic breast cancer who had been treated with AIs in combination with GnRHa or BSO between 2002 and 2015.
Results
The median patient age was 44 years. Overall, 24 (36%) received BSO and 42 (64%) received GnRHa. The clinical benefit rate was higher in the BSO group than in the GnRHa group (88% vs. 69%, p=0.092). Median progression-free survival (PFS) was longer in the BSO group, although statistical significance was not reached (17.2 months vs. 13.3 months, p=0.245). When propensity score matching was performed, the median PFS was 17.2 months for the BSO group and 8.2 months for the GnRHa group (p=0.137). Multivariate analyses revealed that the luminal B subtype (hazard ratio, 1.67; 95% confidence interval [CI], 1.08 to 2.60; p=0.022) and later-line treatment (≥ third line vs. first line; hazard ratio, 3.24; 95% CI, 1.59 to 6.59; p=0.001) were independent predictive factors for a shorter PFS. Incomplete ovarian suppression was observed in a subset of GnRHa-treated patients whose disease showed progression, with E2 levels higher than 21 pg/mL.
Conclusion
Both BSO and GnRHa were found to be effective in our AI-treated premenopausal metastatic breast cancer patient cohort. However, further studies in larger populations are needed to determine if BSO is superior to GnRHa.
Citations
Citations to this article as recorded by
Incomplete ovarian function suppression in premenopausal breast cancer patients treated with gonadotropin-releasing hormone agonists Jinna Lin, Shuqi Zheng, Qiang Liu Cancer Treatment Reviews.2025; 133: 102879. CrossRef
Effectiveness of gonadotropin-releasing hormone agonists for ovarian function suppression in premenopausal patients with hormone receptor-positive breast cancer: a retrospective single-center real-world study Yifei Chen, Ruyan Zhang, Ying Yan, Huiping Li, Guohong Song Breast Cancer Research and Treatment.2024; 206(3): 543. CrossRef
Oophorectomy in Premenopausal Patients with Estrogen Receptor-Positive Breast Cancer: New Insights into Long-Term Effects Fatima Khan, Kristin Rojas, Matthew Schlumbrecht, Patricia Jeudin Current Oncology.2023; 30(2): 1794. CrossRef
Comparison of outcomes in patients with luminal type breast cancer treated with a gonadotropin-releasing hormone analog or bilateral salpingo-oophorectomy: A cohort retrospective study Dwi Ris Andriyanto, Prihantono, Salman Ardi Syamsu, Muhammad Ihwan Kusuma, Joko Hendarto, Indra, Nilam Smaradania, Elridho Sampepajung, Asrul Mappiwali, Muhammad Faruk Annals of Medicine & Surgery.2022;[Epub] CrossRef
Awareness of the Causes Leading to Surgical Ablation of Ovarian Function in Premenopausal Breast Cancer—A Single-Center Analysis Joana Correia Oliveira, Filipa Costa Sousa, Inês Gante, Margarida Figueiredo Dias Medicina.2021; 57(4): 385. CrossRef
Long-term effect of repeated deslorelin acetate treatment in bitches for reproduction control Brändli SP, Palm J, Kowalewski MP, Reichler IM Theriogenology.2021; 173: 73. CrossRef
Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2–) Advanced Breast Cancer: A Systematic Literature Review Gebra Cuyún Carter, Maitreyee Mohanty, Keri Stenger, Claudia Morato Guimaraes, Shivaprasad Singuru, Pradeep Basa, Sheena Singh, Vanita Tongbram, Sherko Kuemmel, Valentina Guarneri, Sara M Tolaney Cancer Management and Research.2021; Volume 13: 6537. CrossRef
Oophorectomy as a Hormonal Ablation Therapy in Metastatic and Recurrent Breast Cancer: Current Indications and Results Islam H. Metwally, Omar Hamdy, Saleh S. Elbalka, Mohamed Elbadrawy, Dina M. Elsaid Indian Journal of Surgical Oncology.2019; 10(3): 542. CrossRef
Targeted Therapy for Premenopausal Women with HR+, HER2− Advanced Breast Cancer: Focus on Special Considerations and Latest Advances Aditya Bardia, Sara Hurvitz Clinical Cancer Research.2018; 24(21): 5206. CrossRef
Tosol Yu, Keun-Yong Eom, Na Young Jang, Kyung Su Kim, Tae Ryool Koo, Jeanny Kwon, Byoung Hyuck Kim, Eunyoung Kang, Sung-Won Kim, Jae-Sung Kim, In Ah Kim
Cancer Res Treat. 2016;48(2):491-498. Published online June 22, 2015
Purpose The purpose of this study is to evaluate objective cosmetic outcomes and factors related to breast-conserving therapy (BCT) using the BCCT.core software.
Materials and Methods Fifty-one patients who received BCT with informed consent were evaluated using the BCCT.core software. Patients were divided into two groups based on the BCCT score: excellent or good (n=42) vs. fair or poor (n=9). Analysis of clinical factors was performed to determine factors affecting cosmetic outcomes.
Results The objective cosmetic outcome of BCT measured using the BCCT.core software was excellent in 10% of patients, good in 72%, and fair in 18%. None of the patients were classified as poor outcome. Tumor characteristics, systemic adjuvant therapy (chemotherapy and hormonal therapy), and radiation dose or energy of electron boost did not show correlation with the score measured by the BCCT.core program (p > 0.05). In univariate analysis, maximum dose within the breast (Dmax), width of tangential field, and excised tumor volume were smaller in patients with excellent or good by the BCCT.core compared to those with fair or poor (Dmax, 110.2±1.5% vs. 111.6±1.7%, p=0.019; width of tangential field, 8.0±1.1 cm vs. 8.6±0.7 cm, p=0.034; excised tumor volume, 64.0±35.8 cm3 vs. 95.3±54.4 cm3, p=0.067). In multivariate analysis, only Dmax was a significant factor for breast cosmetic outcome with a risk ratio of 1.697 (95% confidence interval, 1.006 to 2.863; p=0.047).
Conclusion Objective measurement of cosmetic outcome of BCT using the BCCT.core software was feasible. The cosmetic outcome of BCT may be affected by the maximum dose within the breast.
Citations
Citations to this article as recorded by
Impact of autologous breast reconstruction on bra fit Yen-Tung Liu, Novera H. Khan, Mary Catherine Bordes, Gregory P. Reece, Ashleigh M. Francis, Tzuan A. Chen, Karen Bravo, Mia K. Markey Supportive Care in Cancer.2024;[Epub] CrossRef
Easy Anthropometric Measurements Are Representative of Baseline Values of Breast Q Values in Asymptomatic Women Giuseppe Catanuto, Nicola Rocco, Concetta G. Fichera, Ada Cinquerrui, Martina Rapisarda, Paolo Chiodini, Francesca Magnoni, Patrizia Dorangricchia, Valeria Sebri, Gabriella Pravettoni, Maurizio Bruno Nava, Francesco Caruso Healthcare.2024; 12(2): 268. CrossRef
Outcomes of reconstructive techniques in breast cancer using BCCT. core software Sevgi Kurt, Ahmet Serkan İlgün, Enver Özkurt, Gürsel Soybir, Gül Alço, Çağlar Ünal, Filiz Elbüken Çelebi, Tomris Duymaz, Tuğba Kayan Tapan, Naziye Ak, Çetin Ordu, Vahit Özmen World Journal of Surgical Oncology.2024;[Epub] CrossRef
Evaluating intra and inter-observer bias in the cosmetic rating for random vs. serial assessment of breast photographs Preeti Belani, Rima Pathak, Shraddha Kenekar, Gaurika Pokale, Pallavi Rane, Ashwini Chalke, Tabassum Wadasadawala The Royal College of Radiologists Open.2024; 2: 100152. CrossRef
Comparison of Postoperative Breast Asymmetry Using Vectra 3D Imaging in Prepectoral Versus Subpectoral Implant-Based Breast Reconstruction Seung-Ho Choi, Sang-Oh Lee, Kyu-Jin Chung, Il-Kug Kim, Jun-Ho Lee Journal of Clinical Medicine.2024; 13(23): 7486. CrossRef
Long-term Efficacy and Cosmetic Outcomes of Partial-breast Irradiation Using Multicatheter Interstitial Brachytherapy for Breast-conserving Therapy Kazuhiko SATO, Hiromi FUCHIKAMI, Naoko TAKEDA, Nana NATSUME, Masahiro KATO Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2023; 84(2): 238. CrossRef
Identification of key breast features using a neural network: applications of machine learning in the clinical setting of Plastic Surgery Nitzan Kenig, Javier Monton Echeverria, Luis De la Ossa Plastic & Reconstructive Surgery.2023;[Epub] CrossRef
Breast cancer patient-reported outcome of factors influencing cosmetic satisfaction after breast-conserving therapy A. T. P. M. Brands-Appeldoorn, A. J. G. Maaskant-Braat, L. Janssen, L. A. D. M. van Osch, V. C. G. Tjan-Heijnen, R. M. H. Roumen Breast Cancer.2022; 29(1): 114. CrossRef
BROWSE: A multicentre comparison of nine year outcomes in acellular dermal matrix based and complete submuscular implant-based immediate breast reconstruction-aesthetics, capsular contracture and patient reported outcomes Rebecca L. Wilson, Cliona C. Kirwan, Joe M. O'Donoghue, Richard A. Linforth, Richard K. Johnson, James R. Harvey European Journal of Surgical Oncology.2022; 48(1): 73. CrossRef
Factors related to patient-reported cosmetic outcome after breast-conserving therapy for breast cancer A. T. P. M. Brands-Appeldoorn, R. C. M. Thomma, L. Janssen, A. J. G. Maaskant-Braat, V. C. G. Tjan-Heijnen, R. M. H. Roumen Breast Cancer Research and Treatment.2022; 191(3): 545. CrossRef
Adaptation of BCCT Learning Model in Developing Religious Aspects of Children Abd Hamid Wahid, Muhammad Fajri, Hasan Baharun, Riana Imroatul Fitriyah, Arifatur Risqiyah Jurnal Obsesi : Jurnal Pendidikan Anak Usia Dini.2022; 6(4): 3439. CrossRef
Methods of Esthetic Assessment after Adjuvant Whole-Breast Radiotherapy in Breast Cancer Patients: Evaluation of the BCCT.core Software and Patients’ and Physicians’ Assessment from the Randomized IMRT-MC2 Trial Tobias Forster, Clara Köhler, Melissa Dorn, Matthias Felix Häfner, Nathalie Arians, Laila König, Semi Ben Harrabi, Ingmar Schlampp, Eva Meixner, Vanessa Heinrich, Nicola Weidner, Michael Golatta, André Hennigs, Jörg Heil, Holger Hof, David Krug, Jürgen De Cancers.2022; 14(12): 3010. CrossRef
Feasibility of anomaly score detected with deep learning in irradiated breast cancer patients with reconstruction Dong-Yun Kim, Soo Jin Lee, Eun-Kyu Kim, Eunyoung Kang, Chan Yeong Heo, Jae Hoon Jeong, Yujin Myung, In Ah Kim, Bum-Sup Jang npj Digital Medicine.2022;[Epub] CrossRef
Breast Oncoplastic Resections: No Innovation Without Evaluation Sherif Monib, Mohamed Farag, Mohamed Ibrahim Indian Journal of Surgery.2021; 83(S2): 409. CrossRef
Cosmetic Outcomes of a Phase 1 Dose Escalation Study of 5-Fraction Stereotactic Partial Breast Irradiation for Early Stage Breast Cancer Asal Rahimi, Howard E. Morgan, Dong W. Kim, Yuanyuan Zhang, Marilyn Leitch, Rachel Wooldridge, Sally Goudreau, Barbara Haley, Roshni Rao, Aeisha Rivers, Ann E. Spangler, Ryan T. Jones, Stella Stevenson, Jason Staley, Kevin Albuquerque, Chul Ahn, Sarah Neu International Journal of Radiation Oncology*Biology*Physics.2021; 110(3): 772. CrossRef
Comparative study between laparoscopically harvested omental flap and glandular flap in immediate reconstruction after conservative surgery in breast cancer Waleed Y. El‐Sherpiny, Abdulhamid M. Abdelshafi, Mohamed Ghazaly, Ayman A. Elnemr, Ahmed A. Darwish, Mohamed A. Mlees Surgical Practice.2021; 25(2): 92. CrossRef
Reliability of the BCCT.core software in evaluation of breast cosmesis – A systematic review Stami Trakis, Heidi Lord, Peter Graham, Ritin Fernandez Journal of Medical Imaging and Radiation Oncology.2021; 65(6): 817. CrossRef
New criteria for breast symmetry evaluation after breast conserving surgery for cancer RENÉ ALOISIO DA COSTA VIEIRA, GABRIELE BILLER, FABIOLA CRISTINA BRANDINI DA SILVA, JONATHAS JOSÉ DA SILVA, MARCO ANTÔNIO DE OLIVEIRA, ANTÔNIO BAILÃO-JUNIOR Revista do Colégio Brasileiro de Cirurgiões.2021;[Epub] CrossRef
Use of Symmetry Assessment Methods in the Context of Breast Surgery Javier Monton, Asia Torres, Maria Gijon, Luis Chang-Azancot, Nitzan Kenig, P. Camelia Trandafir, Joaquin Jordan, Ricardo Insausti Aesthetic Plastic Surgery.2020; 44(5): 1440. CrossRef
Visual Breast Asymmetry Assessment with Optical-Flow Algorithm Javier Monton, Nitzan Kenig, Ricardo Insausti, Joaquin Jordan Journal of Medical Systems.2020;[Epub] CrossRef
Nueva metodología para medir simetría frontal en pacientes reconstruidas por cáncer de mama Lenia Sánchez Wals, Carlos Acosta-Batista, Oscar Luis Vera Pérez, Juan Jesús Lence Anta, Marco Marcasciano Revista de Senología y Patología Mamaria.2019; 32(4): 133. CrossRef
Objective assessment of flap volume changes and aesthetic results after adjuvant radiation therapy in patients undergoing immediate autologous breast reconstruction Yujin Myung, Yousung Son, Tae-hyun Nam, Eunyoung Kang, Eun-Kyu Kim, In Ah Kim, Keun-Yong Eom, Chan Yeong Heo, Jae Hoon Jeong, Fabio Santanelli, di Pompeo d'Illasi PLOS ONE.2018; 13(5): e0197615. CrossRef